Stock listing
NASDAQ:VRXA Veraxa Biotech AG Stock
Follow Veraxa Biotech AG into a list and get an email when it puts out news.
Share price · NASDAQ:VRXA
$1.04 USD +0.01 (+1.0%)
Close on Nov 20, 2026
- Day range
- $1.03 – $1.06 USDNov 20, 2026
- Volume
- 114,628 sharesNov 20, 2026
- Market cap
- $147.1M USDAt the close on Nov 20, 2026 · price × 141.4M shares outstanding
- Traded on an average day
- $364,199 USDMedian day 137,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VRXA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.04 | +0.01 | +1.0% | $1.03 | $1.06 | $1.03 | 114,628 | |
| $1.03 | -0.01 | -1.0% | $1.04 | $1.07 | $1.03 | 104,297 | |
| $1.04 | -0.005 | -0.5% | $1.03 | $1.065 | $1.03 | 111,524 | |
| $1.045 | -0.065 | -5.9% | $1.08 | $1.11 | $1.04 | 55,192 | |
| $1.11 | -0.04 | -3.5% | $1.15 | $1.18 | $1.06 | 114,127 | |
| $1.15 | -0.11 | -8.7% | $1.23 | $1.28 | $1.14 | 105,720 | |
| $1.26 | +0.19 | +17.8% | $1.10 | $1.33 | $1.10 | 270,099 | |
| $1.07 | +0.06 | +5.9% | $1.00 | $1.15 | $1.00 | 163,791 | |
| $1.01 | +0.06 | +6.3% | $0.97 | $1.07 | $0.938 | 171,879 | |
| $0.95 | -0.002 | -0.2% | $0.96 | $0.97 | $0.90 | 222,341 | |
| $0.952 | +0.002 | +0.2% | $1.01 | $1.05 | $0.95 | 151,699 | |
| $0.95 | -0.04 | -4.0% | $0.99 | $1.018 | $0.95 | 103,122 | |
| $0.99 | -0.04 | -3.9% | $1.02 | $1.055 | $0.962 | 53,496 | |
| $1.03 | -0.11 | -9.6% | $1.14 | $1.15 | $1.03 | 286,810 | |
| $1.14 | +0.01 | +0.9% | $1.18 | $1.249 | $1.075 | 259,928 | |
| $1.13 | +0.15 | +15.3% | $0.97 | $1.21 | $0.97 | 363,015 | |
| $0.98 | -0.02 | -2.0% | $1.02 | $1.02 | $0.97 | 68,905 | |
| $1.00 | +0.02 | +2.0% | $1.00 | $1.02 | $0.98 | 95,381 | |
| $0.98 | -0.02 | -2.0% | $1.00 | $1.03 | $0.95 | 161,639 | |
| $1.00 | -0.03 | -2.9% | $1.04 | $1.06 | $0.99 | 137,900 | |
| $1.03 | -0.03 | -2.8% | $1.08 | $1.08 | $1.03 | 171,300 | |
| $1.06 | +0.05 | +5.0% | $1.05 | $1.13 | $1.05 | 198,100 | |
| $1.01 | +0.01 | +1.0% | $1.09 | $1.09 | $0.99 | 126,400 | |
| $1.00 | -0.11 | -9.9% | $1.10 | $1.10 | $1.00 | 119,000 | |
| $1.11 | +0.01 | +0.9% | $1.15 | $1.15 | $1.08 | 125,500 | |
| $1.10 | -0.01 | -0.9% | $1.13 | $1.15 | $1.06 | 114,500 | |
| $1.11 | -0.09 | -7.5% | $1.20 | $1.20 | $1.08 | 61,500 | |
| $1.20 | +0.06 | +5.3% | $1.20 | $1.35 | $1.12 | 741,300 | |
| $1.14 | -0.12 | -9.5% | $1.22 | $1.30 | $1.13 | 156,100 | |
| $1.26 | +0.17 | +15.6% | $1.08 | $1.409 | $1.07 | 1,860,900 | |
| $1.09 | -0.11 | -9.2% | $1.19 | $1.21 | $1.09 | 211,900 | |
| $1.20 | +0.12 | +11.1% | $1.16 | $1.32 | $1.10 | 749,200 | |
| $1.08 | -0.05 | -4.4% | $1.12 | $1.147 | $1.04 | 395,300 | |
| $1.13 | 0.00 | 0.0% | $1.13 | $1.16 | $1.12 | 153,200 | |
| $1.13 | -0.06 | -5.0% | $1.15 | $1.15 | $1.105 | 150,200 | |
| $1.19 | -0.06 | -4.8% | $1.25 | $1.25 | $1.18 | 64,900 | |
| $1.25 | -0.06 | -4.6% | $1.31 | $1.31 | $1.175 | 119,500 | |
| $1.31 | -0.06 | -4.4% | $1.37 | $1.37 | $1.30 | 52,800 | |
| $1.37 | -0.04 | -2.8% | $1.43 | $1.44 | $1.36 | 48,500 | |
| $1.41 | 0.00 | 0.0% | $1.43 | $1.45 | $1.382 | 55,800 | |
| $1.41 | +0.02 | +1.4% | $1.37 | $1.44 | $1.37 | 23,300 | |
| $1.39 | -0.02 | -1.4% | $1.44 | $1.44 | $1.38 | 43,400 | |
| $1.41 | -0.01 | -0.7% | $1.42 | $1.436 | $1.36 | 59,500 | |
| $1.42 | -0.04 | -2.7% | $1.45 | $1.52 | $1.42 | 49,100 | |
| $1.46 | -0.01 | -0.7% | $1.50 | $1.515 | $1.45 | 16,400 | |
| $1.47 | -0.04 | -2.6% | $1.50 | $1.53 | $1.46 | 48,000 | |
| $1.51 | -0.01 | -0.7% | $1.56 | $1.59 | $1.495 | 47,600 | |
| $1.52 | -0.11 | -6.7% | $1.61 | $1.699 | $1.50 | 52,300 | |
| $1.63 | -0.02 | -1.2% | $1.63 | $1.72 | $1.60 | 64,700 | |
| $1.65 | 0.00 | 0.0% | $1.68 | $1.72 | $1.62 | 88,900 | |
| $1.65 | +0.06 | +3.8% | $1.58 | $1.682 | $1.57 | 400,100 | |
| $1.59 | -0.01 | -0.6% | $1.62 | $1.65 | $1.56 | 188,500 | |
| $1.60 | -0.16 | -9.1% | $1.81 | $1.90 | $1.56 | 468,700 | |
| $1.76 | +0.23 | +15.0% | $1.57 | $1.97 | $1.531 | 3,582,300 | |
| $1.53 | +0.15 | +10.9% | $1.38 | $1.68 | $1.371 | 560,000 | |
| $1.38 | -0.02 | -1.4% | $1.42 | $1.435 | $1.36 | 176,200 | |
| $1.40 | +0.05 | +3.7% | $1.38 | $1.543 | $1.27 | 384,800 | |
| $1.35 | 0.00 | 0.0% | $1.39 | $1.39 | $1.32 | 296,300 | |
| $1.35 | -0.09 | -6.2% | $1.43 | $1.45 | $1.32 | 313,600 | |
| $1.44 | -0.20 | -12.2% | $1.65 | $1.685 | $1.365 | 495,000 | |
| $1.64 | -0.09 | -5.2% | $1.85 | $1.85 | $1.57 | 425,400 | |
| $1.73 | -0.05 | -2.8% | $1.78 | $1.825 | $1.72 | 145,700 | |
| $1.78 | -0.17 | -8.7% | $1.98 | $2.00 | $1.75 | 301,900 | |
| $1.95 | +0.06 | +3.2% | $1.86 | $2.00 | $1.85 | 80,200 | |
| $1.89 | +0.03 | +1.6% | $1.88 | $1.95 | $1.85 | 37,100 |
- Ticker
- NASDAQ:VRXA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 13, 2026
VERAXA Biotech (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress
Latest news
VERAXA Biotech (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress
Oct 13, 2026
Closed $1.20 (+5.3%) on Oct 13, 2026
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
Oct 13, 2026
Closed $1.20 (+5.3%) on Oct 13, 2026
VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
Oct 7, 2026
Closed $1.20 (+11.1%) on Oct 7, 2026
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
Oct 7, 2026
Closed $1.20 (+11.1%) on Oct 7, 2026
VERAXA Biotech (NASDAQ: VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress
Sep 24, 2026
Closed $1.41 (+1.4%) on Sep 24, 2026
VERAXA Biotech (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
Sep 22, 2026
Closed $1.41 (-0.7%) on Sep 22, 2026
VERAXA Biotech (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
Sep 18, 2026
Closed $1.46 (-0.7%) on Sep 18, 2026
VERAXA Biotech (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy
Sep 16, 2026
Closed $1.51 (-0.7%) on Sep 16, 2026
VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer
Sep 8, 2026
Closed $1.60 (-9.1%) on Sep 8, 2026
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Sep 4, 2026
Closed $1.76 (+15.0%) on Sep 4, 2026
Veraxa Biotech AG on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 42 in the last 12 months · 42 in all · newest Oct 13, 2026 · oldest 2026
- Decks
- 1 deck · latest Apr 23, 2025
Valuation
EV/sales 5,202× against a median of 2.7×: the highest of 7 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · price Nov 20, 2026
- Enterprise value
- $145.1M USD
- P/E
- Loss
- EV/sales
- 5,202×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 66.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.11
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Veraxa Biotech AG · NASDAQ:VRXA | US$147.1M | US$145.1M | n/a | 5,202× | n/a | n/a | n/a | n/a | 1.11 |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541 | US$152.0M | US$64.59M | n/a | 2.9× | n/a | 1.6× | −141.7% | 0.6× | n/a |
| Saniona AB · OMXSTO:SANION | US$151.6M | US$104.0M | 8.4× | 2.5× | 5.2× | 2.8× | 43.2% | 0.0× | n/a |
| Palisade Bio, Inc. · NASDAQ:PALI | US$150.6M | US$36.96M | n/a | 73.9× | n/a | 1.3× | n/a | 0.0× | 1.41 |
| Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN | US$150.3M | US$80.67M | n/a | n/a | n/a | 4.9× | n/a | 0.0× | 1.95 |
| ProQR Therapeutics N.V. · NASDAQ:PRQR | US$146.8M | US$49.73M | n/a | 2.2× | n/a | 2.0× | −210.7% | 0.2× | 1.73 |
| ALX Oncology Holdings Inc. · NASDAQ:ALXO | US$146.6M | US$9.57M | n/a | n/a | n/a | 1.2× | n/a | 0.1× | 0.68 |
| Bicycle Therapeutics PLC · NASDAQ:BCYC | US$146.1M | −US$323.8M | n/a | −3.9× | n/a | 0.3× | −169.8% | 0.0× | 1.59 |
| BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOT | US$145.3M | −US$46.23M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.49 |
| TYK Medicines, Inc. Class H · HKEX:2410 | US$144.9M | US$137.1M | n/a | n/a | n/a | 3.7× | n/a | 0.6× | n/a |
| Sutro Biopharma, Inc. · NASDAQ:STRO | US$142.8M | US$259.6M | n/a | 5.8× | n/a | n/a | −344.2% | n/a | 1.14 |
| Median of the others | US$146.7M | US$57.16M | 8.4× | 2.7× | 5.2× | 1.6× | −169.8% | 0.0× | 1.49 |
Team and board
Officers
| Officer | Role |
|---|---|
| Carl von Halem | Interim Chief Financial Officer and Successor to Torsten Bürgermeister |
| Raju Willener | MBA, CFO |
| Christoph Erkel | Ph.D., CSO |
Board
| Director | Role |
|---|---|
| Oliver R. Baumann | Chair of the Board |
| Christoph Antz | Director |
| Christoph Ziegler | Independent Director |
| Marc Grüninger | Chair of the Audit Committee |
| Warren Hosseinion | Independent Director |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| SPAC Merger (April 2025) | SPAC merger | 28 slides | Apr 23, 2025 |
Financials
Annual, in CHF
Income statement
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 23.4K | 0 | 0 |
| Cost of revenue | 7.96K | 0 | |
| Gross profit | 15.5K | 0 | |
| Research and development | 10.3M | 6.31M | 4.26M |
| Selling, general and administrative | 53.9M | 20.7M | 10.5M |
| Operating income | -66.2M | -28.9M | -16.7M |
| Depreciation and amortization | 1.97M | 1.88M | 1.85M |
| EBITDA | -64.2M | -27.0M | -14.8M |
| Interest expense | 3.55K | 291 | 1.09K |
| Income before tax | -67.0M | -28.8M | -17.7M |
| Net income | -66.6M | -28.1M | -16.5M |
| Earnings per share, basic | -0.47 | -0.20 | -0.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | 1.61M | 5.36M | 11.4M |
| Current assets | 2.88M | 5.61M | 11.9M |
| Goodwill | 22.8M | 22.8M | 22.8M |
| Total assets | 80.8M | 84.8M | 91.9M |
| Accounts payable | 1.39M | 488.5K | 611.6K |
| Current liabilities | 6.61M | 2.55M | 1.61M |
| Total liabilities | 96.6M | 53.7M | 36.8M |
| Shareholders' equity | -15.8M | 31.1M | 55.1M |
| Shares outstanding | 141.4M | 141.4M | 141.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash from operations | -9.90M | -7.72M | -7.27M |
| Capital spending | -437.2K | -120.9K | -232.3K |
| Free cash flow | -10.3M | -7.84M | -7.50M |
| Cash from financing | 6.59M | 1.85M | 12.5M |
| Change in cash | -3.75M | -5.99M | 4.25M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Oct 15, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 14, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Sep 4, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Sep 4, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 4, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
All 57 filings
Cap table
Built by 6ix from Veraxa Biotech AG’s releases
- Common shares
- 141,407,813
- Fully diluted
- 141,407,813
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 141,407,813 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 141,407,813 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Warren Hosseinion Other companies: Cardio Diagnostics Holdings Inc. (Non-Executive Chairman of the Board · Since at least Nov 5, 2026); General Purpose Acquisition Corp. (Director · Since at least Dec 2, 2025); Nutex Health Inc. (President and Director · Since at least Mar 1, 2025) | Independent Director · Since at least Jun 9, 2026 |
| Carl von Halem | Interim Chief Financial Officer and Successor to Torsten Bürgermeister · Since at least Jul 10, 2026 |
| Christoph Antz | Director · Since at least Jun 9, 2026 |
| Christoph Erkel | Ph.D., CSO · Since Jul 23, 2026 |
| Christoph Ziegler | Independent Director · Since at least Jun 9, 2026 |
| Heinz Schwer | Chief Business Officer · Since at least Jun 9, 2026 |
| Marc Grüninger | Chair of the Audit Committee · Since at least Jun 9, 2026 |
| Oliver R. Baumann | Chair of the Board · Since at least Jun 9, 2026 |
| Raju Willener | MBA, CFO · Since at least Sep 1, 2026 |
| Torsten Georg Friedrich Buergermeister | Chief Financial Officer · Since at least Jun 9, 2026 |
Log in to ask 6ix AI your own questions about Veraxa Biotech AG.